

Solid Tumors

**A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)**

**Trial Status**  
Recruiting

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT06331598 2022-003708-33  
ML43332

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study is being conducted to evaluate efficacy parameters (disease free survival [DFS] and overall survival [OS]) of atezolizumab and atezolizumab in combination with tiragolumab in TMB-H or MSI-H as adjuvant treatment after standard radical intended treatment in participants with intermediate-high risk of recurrence.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

**NCT06331598 2022-003708-33 ML43332**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No